GW Pharma's (GWPH) Price Target Raised to $152 at Morgan Stanley

GW Pharma (GWPH) PT Raised to $138 at Leerink Partners

Leerink Partners analyst Paul Matteis reiterated an Outperform rating and raised his price target on GW Pharma (NASDAQ: GWPH) to $138.00 (from $130.00) after the company announced positive results for its 1st Phase 3 study for Epidiolex in Lennox-Gastaut Syndrome (LGS).

"... our view remains positive after the... More

GW Pharma (GWPH) Epidiolex Data in LGS 'Looks Good' - Leerink

Leerink Partners analyst Paul Matteis offered some initial thoughts on GW Pharma (NASDAQ: GWPH) after the company announced positive top-line results for Epidiolex in Lennox Gastaut Syndrome (LGS).

Matteis commented, "The data show a 22% seizure reduction relative to placebo, suggesting that Epidiolex's... More

GW Pharma (GWPH) Announces Positive Top-Line Data from Epidiolex Phase 3

GW Pharmaceuticals plc (Nasdaq: GWPH) announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. In this trial, Epidiolex, when added as an adjunct to the patients current treatment, achieved the primary endpoint of a significant reduction in the monthly frequency of drop seizures assessed over the entire 14-week treatment period compared with placebo (p=0.0135). This trial follows the announcement in March 2016 of positive results in a... More

Janney Montgomery Scott Starts GW Pharma (GWPH) at Sell

Janney Montgomery Scott initiated coverage on GW Pharma (NASDAQ: GWPH) with a Sell rating and a price target of $40.00.

For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.

Shares of GW Pharma closed at $83.31 yesterday.